Kenneth Dzike

Kenneth Dzike practices at Lehigh Valley Hospital-Cedar Crest in Allentown, Pennsylvania, part of Thomas Jefferson University.

Kenneth Dzike's NPI, 1376956011, was assigned on June 10, 2014. Kenneth Dzike holds Pennsylvania license MD464759.

Kenneth Dzike's primary practice is Lehigh Valley Hospital-Cedar Crest, at 1200 South Cedar Crest Boulevard, Allentown, PA 18103 in Lehigh County. The practice phone is (610) 402-8000.

Kenneth Dzike's primary practice is Lehigh Valley Hospital-Cedar Crest in Allentown, Pennsylvania, part of Thomas Jefferson University. The medical group on file is Lehigh Valley Physician Group (LVPG).

Dmand AI tracks the electronic health record (EHR) system at each site where Kenneth Dzike practices. Vendor and product names are available with a free account.

Emergency medicine is Kenneth Dzike's primary specialty in the NPI Registry, under taxonomy code 207P00000X. Kenneth Dzike is licensed in Pennsylvania.

CMS data shows 496 Medicare services from Kenneth Dzike across 6 procedure codes in 2024, for 443 Medicare patients. Medicare paid $51,909 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 443 Medicare patients who saw Kenneth Dzike in 2024. The largest group is 75 to 84, with 142 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 20% are also on Medicaid. Their average risk score is 2.06, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Kenneth Dzike's median patient age at 46, with 60% women.

In 2024, Kenneth Dzike wrote 81 Medicare Part D claims for 64 patients. 96% of them were for generic drugs. CMS names the drug for 14 of them, across 1 drug with 11 or more claims each, at $71 in total drug cost. In 2023, CMS named 34 claims across 3 drugs.

Kenneth Dzike accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 10 general payments to Kenneth Dzike from 2 drug and device companies from 2016 to 2018. Food and beverage make up the largest share, 100% of the total. Pfizer Inc. paid the most, $104.